(00:21) Asit Sharma and Dylan Lewis discuss: - How the airline industry’s focus on capacity and being able to supply more flights means fares are low, even in the face of record demand. - Eli Lilly’s $3.2B acquisition of Morphic, why it’s interested in the inflammatory bowel disease markets, and a few risks to keep in mind for the high-flying provider of weight-loss drugs. (14:39) Fool analyst Kirsten Guerra talks with Mary Long about her investing journey, and a career pivot that took her from rocks to stocks. Companies discussed: DAL, UAL, AAL, JBLU, LUV, LLY, MORF Host: Dylan Lewis Guests: Asit Sharma, Kirsten Guerra, Mary Long Producer: Ricky Mulvey Engineers: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Motley Fool Money
Transcribed and ready to explore now
Interview with MichaelAaron Flicker: Hacking the Human Mind
21 Dec 2025
Motley Fool Money
How to Review and Rebalance Your Portfolio
20 Dec 2025
Motley Fool Money
Hidden Gem Stocks We Love at the End of the Year
18 Dec 2025
Motley Fool Money
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
$70 billion and Chill
09 Dec 2025
Motley Fool Money
Profitability Predictions and Paramount Punches Back
08 Dec 2025
Motley Fool Money